Full-Time

Senior Therapeutic Specialist

Oncology

Gilead Sciences

Gilead Sciences

10,001+ employees

Biopharmaceutical firm developing HIV/AIDS therapies

No salary listed

Edinburgh, UK

In Person

Field-based role based in Edinburgh, serving Scotland and Northern England.

Category
Biology & Biotech (1)

Get referred to Gilead Sciences

See people who can refer or advise you

Requirements
  • Expert oncology scientific and technical skills
  • Demonstrated emotional intelligence
  • Strong business acumen
  • Passion for finding solutions to complex problems for patient care
  • Strong existing networks in the oncology ecosystem, preferably in breast cancer
  • Ability to engage with the whole multi-disciplinary team and understand stakeholders' roles and needs
  • Willingness to work as part of a cross-functional team
Responsibilities
  • Oncology Scientific Expertise (preferred) Deep understanding and navigates oncology hospital environments
  • Oncology Scientific Expertise (preferred) Expert scientific knowledge in oncology who is a scientific knowledge expert and clinical resource for oncology to their customer
  • Oncology Scientific Expertise (preferred) Has established strategic relationships with MDT, opinion leaders & the senior account level leadership as well as other policy shaping and decision makers
  • Key Account Management Expertise in insights generation, strategy development and execution, working as part of a cross-functional team. Measures performance and adapts for success
  • Deep understanding and navigates complex hospital environments and understands the needs and challenges of various stakeholders at all levels within the account and partner to find win-win-win solutions
  • Development and execution of strategic account plans including prioritised individual stakeholder and account activity plan
  • Develop strategic relationships with multidisciplinary team members, opinion leaders & the senior account level leadership as well as other policy shaping and decision makers
  • Partners and collaborates with the oncology multi-disciplinary team as a trusted partner for a thorough understanding of each stakeholder’s role and needs
  • Selling Skills Excellence in call planning
  • Strong strategic partnering ability externally across multiple stakeholder groups
  • Excellent questioning skills to identify opportunities and unmet needs
  • Ability to tailor product solutions to meet the needs of customers
  • Committing stakeholders to action, and ensuring follow-up
  • Understand future trends and shape ecosystems to enable introduction of treatments
  • Understand the needs and challenges of various stakeholders at all levels within the account and partner to find win-win-win solutions
  • Develops in-depth market interpretation of sales analysis data
  • Thrives in an agile oncology setting with dynamic release and fast uptake of products
  • Advanced business acumen to lead the development and execution of strategic account and commercial plans which will include clear goals and tactics aligned with corporate and commercial business objectives
  • Takes full ownership to deliver sales targets in assigned territory and supports delivery of team targets
  • Initiates systems to monitor sales progress and action plans
  • Manages territory budgets for sales and expenditure
  • Represents company at professional events and promote company products at such events
  • Leads sales initiatives within the market to deliver to plan
  • Completes necessary administrative tasks in a timely manner e.g. updating customer database, expenses etc
  • Responsible for achieving the competency levels required in the role
  • Compliance with all legal and regulatory agencies is required
Desired Qualifications
  • Deep understanding and navigates oncology hospital environments (preferred)
  • Expert scientific knowledge in oncology who is a scientific knowledge expert and clinical resource for oncology to their customer (preferred)
  • Has established strategic relationships with MDT, opinion leaders & the senior account level leadership as well as other policy shaping and decision makers (preferred)

Gilead Sciences discovers, develops, and markets medicines to treat HIV/AIDS, liver diseases, cancer, inflammatory and respiratory diseases, and cardiovascular conditions. Its products reach patients globally after regulatory approval, sold through doctors, hospitals, and pharmacies. The company relies on a large, diverse R&D pipeline and strategic partnerships to expand its therapies and reach, including collaborations like SAP Ariba to improve sourcing. Its goal is to improve health equity by expanding access to medicines and promoting sustainable healthcare practices worldwide.

Company Size

10,001+

Company Stage

IPO

Headquarters

Foster City, California

Founded

1987

Get referred to Gilead Sciences

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 revenue rose 10% to $7.8 billion, beating estimates on August 4.
  • PrEP sales exceeded $1 billion, and Yeztugo reached $232 million in Q2.
  • FDA accepted weekly Yeztugo tablets, with a February 2, 2027 PDUFA date.

What critics are saying

  • Merck’s Idvynso and GSK’s Cabenuva attack Gilead’s HIV moat this year.
  • Biktarvy exclusivity ends in 2036, concentrating replacement pressure on next-generation regimens.
  • HIV supplies about 70% of revenue, so a franchise stumble hits valuation hard.

What makes Gilead Sciences unique

  • Biktarvy anchors Gilead’s HIV franchise, generating $3.8 billion in Q2 2026.
  • Yeztugo made Gilead the first six-month injectable PrEP leader in 2026.
  • Lenacapavir enables weekly oral and biannual dosing, differentiating Gilead’s HIV platform.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Paid family time off and paid parental time off

Generous 401(k) contribution matching

Comprehensive medical plans that cover both physical and mental healthcare

Global Wellbeing Reimbursement

Time Off

Global Volunteer Day

Giving Together Program

Employee Support Programs

Flexible Work Options

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
Yahoo Finance
Aug 8th, 2026
Gilead raises 2026 outlook on HIV and PrEP strength, targets $30B in sales

Gilead Sciences reported second-quarter 2026 results that exceeded expectations, with revenues of $7.8 billion, up 10% year over year, and a non-GAAP loss per share of $6.75 beating consensus estimates. The company raised its full-year guidance for product sales excluding Veklury to $29.8 billion to $30.1 billion, an increase of $350 million at the midpoint. HIV sales drove growth, rising 12% in the quarter. Quarterly PrEP sales surpassed $1 billion for the first time, putting the prevention business at a $4 billion annual run rate. Gilead now expects full-year HIV sales to increase 9% to 10%, up from its prior 8% outlook. Biktarvy generated $3.8 billion in sales, whilst newer product Yeztugo delivered $232 million. The company maintained its approximately $1 billion full-year Yeztugo sales target, with more than 70% of users returning for reinjection at six months.

Yahoo Finance
Aug 4th, 2026
Gilead Q2 sales rise 8% to $7.8B, beating estimates despite acquisition-related loss

Gilead Sciences reported second-quarter product sales rose 8%, driven by double-digit growth in HIV drugs. Overall revenue increased 10% to $7.8 billion, surpassing Wall Street's $7.4 billion estimate. HIV sales grew 12%, whilst cancer drug Trodelvy and liver disease drug Livdelzi also performed strongly. HIV prevention drug Yeztugo generated $232 million, exceeding forecasts, whilst Descovy sales jumped 48% to $967 million. The company posted a quarterly loss due to acquisition costs. Gilead narrowed its projected full-year loss and slightly raised its revenue outlook to between $30.1 billion and $30.4 billion. The California-based biotech firm expressed confidence in achieving $1 billion in annual Yeztugo sales.

Yahoo Finance
Aug 3rd, 2026
California Supreme Court rules for Gilead, rejects 'duty to innovate' in case with 24,000 HIV patients

California's Supreme Court ruled 6-1 that drugmakers have no legal duty to develop safer alternatives to existing safe medications, siding with Gilead Sciences in a closely watched case. The decision dismissed negligence claims from approximately 24,000 patients using Gilead's HIV drug. Patients argued the company should have developed an alternative with fewer side effects more than 20 years ago. Justice Joshua Groban wrote that imposing a "duty to innovate" would require juries to second-guess complex scientific judgements. He warned it could create substantial burdens and risk adverse consequences for pharmaceutical innovation and public health. The ruling reversed a February 2024 appeals court decision. Dozens of trade groups and major drugmakers, including Pfizer, Merck and Johnson & Johnson, supported Gilead's appeal. HIV drugs accounted for 70% of Gilead's $29.4 billion revenue last year.

MarketBeat
Jul 28th, 2026
Gilead Sciences (GILD) expected to post quarterly earnings on Monday.

Gilead Sciences (GILD) expected to post quarterly earnings on Monday. July 28, 2026 Key points. * Gilead Sciences is expected to report Q2 2026 results after Monday's market close. Analysts forecast revenue of approximately $7.40 billion and a loss of $7.25 per share; the earnings call is scheduled for Tuesday, August 4. * Gilead's latest quarter exceeded expectations, with EPS of $2.03 versus the $1.91 consensus and revenue of $6.96 billion, up 4.4% year over year. * The stock recently traded at $133.57, while analysts maintain a "Moderate Buy" consensus and an average price target of $158.30. Gilead also pays a quarterly dividend of $0.82 per share, yielding about 2.5%. * MarketBeat previews top five stocks to own in August. Gilead Sciences (NASDAQ:GILD - Get Free Report) is expected to be announcing its Q2 2026 results after the market closes on Monday, August 3rd. Analysts expect Gilead Sciences to announce earnings of ($7.2479) per share and revenue of $7.4001 billion for the quarter. Gilead Sciences has set its FY 2026 guidance at -1.050-0.650 EPS. Investors can check the company's upcoming Q2 2026 earning results page for the latest details on the call scheduled for Tuesday, August 4, 2026 at 4:30 PM ET. Gilead Sciences (NASDAQ:GILD - Get Free Report) last posted its quarterly earnings data on Thursday, May 7th. The biopharmaceutical company reported $2.03 EPS for the quarter, topping analysts' consensus estimates of $1.91 by $0.12. Gilead Sciences had a return on equity of 48.19% and a net margin of 30.99%.The company had revenue of $6.96 billion for the quarter, compared to the consensus estimate of $6.91 billion. During the same quarter in the previous year, the business earned $1.81 EPS. The company's quarterly revenue was up 4.4% compared to the same quarter last year. On average, analysts expect Gilead Sciences to post $-1 EPS for the current fiscal year and $10 EPS for the next fiscal year. Gilead Sciences price performance. GILD stock traded up $3.05 during trading hours on Tuesday, hitting $133.57. 2,655,524 shares of the stock traded hands, compared to its average volume of 7,097,293. The stock has a 50-day simple moving average of $129.56 and a 200 day simple moving average of $135.68. The company has a market cap of $165.84 billion, a P/E ratio of 18.19 and a beta of 0.32. Gilead Sciences has a one year low of $108.46 and a one year high of $157.29. The company has a current ratio of 1.97, a quick ratio of 1.77 and a debt-to-equity ratio of 0.89. Gilead Sciences announces dividend. The firm also recently disclosed a quarterly dividend, which was paid on Monday, June 29th. Stockholders of record on Monday, June 15th were given a dividend of $0.82 per share. The ex-dividend date was Monday, June 15th. This represents a $3.28 annualized dividend and a dividend yield of 2.5%. Gilead Sciences's dividend payout ratio (DPR) is 44.69%. Insider activity. In other news, CEO Daniel Patrick O'day sold 15,000 shares of Gilead Sciences stock in a transaction on Wednesday, July 1st. The stock was sold at an average price of $126.29, for a total transaction of $1,894,350.00. Following the transaction, the chief executive officer owned 607,133 shares in the company, valued at approximately $76,674,826.57. The trade was a 2.41% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Johanna Mercier sold 3,000 shares of the company's stock in a transaction on Monday, June 15th. The shares were sold at an average price of $123.92, for a total value of $371,760.00. Following the transaction, the insider directly owned 124,234 shares in the company, valued at $15,395,077.28. The trade was a 2.36% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 67,000 shares of company stock worth $8,687,140 over the last quarter. Corporate insiders own 0.30% of the company's stock. Hedge funds weigh in on Gilead Sciences. Several institutional investors and hedge funds have recently bought and sold shares of the business. Vermillion & White Wealth Management Group LLC lifted its position in shares of Gilead Sciences by 71.4% in the fourth quarter. Vermillion & White Wealth Management Group LLC now owns 204 shares of the biopharmaceutical company's stock worth $25,000 after purchasing an additional 85 shares in the last quarter. Quattro Advisors LLC acquired a new stake in shares of Gilead Sciences during the fourth quarter worth approximately $26,000. Swiss RE Ltd. purchased a new position in Gilead Sciences during the fourth quarter valued at approximately $31,000. Mcguire Capital Advisors Inc. purchased a new position in Gilead Sciences during the fourth quarter valued at approximately $43,000. Finally, Palisade Asset Management LLC acquired a new position in Gilead Sciences in the 3rd quarter valued at approximately $46,000. Hedge funds and other institutional investors own 83.67% of the company's stock. Analysts set new price targets. Several equities analysts have recently issued reports on the stock. Maxim Group raised shares of Gilead Sciences from a "hold" rating to a "buy" rating and set a $165.00 price objective on the stock in a research note on Wednesday, May 20th. Citigroup lifted their price target on shares of Gilead Sciences from $156.00 to $165.00 and gave the stock a "buy" rating in a research report on Monday, April 13th. Leerink Partners cut Gilead Sciences from an "outperform" rating to a "market perform" rating and dropped their price target for the company from $146.00 to $127.00 in a report on Tuesday, July 21st. The Goldman Sachs Group boosted their target price on Gilead Sciences from $125.00 to $130.00 and gave the stock a "neutral" rating in a research report on Friday, April 17th. Finally, Royal Bank Of Canada reduced their target price on Gilead Sciences from $122.00 to $120.00 and set a "sector perform" rating for the company in a report on Tuesday, July 7th. Twenty-five research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company's stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $158.30. About Gilead Sciences. Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world. Gilead's product portfolio is anchored by antiviral therapies for HIV and viral hepatitis. This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected]. Before you consider Gilead Sciences, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Gilead Sciences wasn't on the list. While Gilead Sciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys. The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge - and the key risks investors should watch as the global AI buildout accelerates.

Business Insider
Jul 25th, 2026
Gilead Sciences (GILD) gets a Hold from RBC Capital.

Gilead Sciences (GILD) gets a Hold from RBC Capital. Jul. 25, 2026, 08:45 AM RBC Capital analyst Brian Abrahams maintained a Hold rating on Gilead Sciences on July 23 and set a price target of $120.00. The company's shares closed yesterday at $130.86. * Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions * Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks According to TipRanks, Abrahams is a 5-star analyst with an average return of 14.5% and a 54.40% success rate. Abrahams covers the Healthcare sector, focusing on stocks such as Gilead Sciences, Biogen, and Neurocrine. In addition to RBC Capital, Gilead Sciences also received a Hold from Goldman Sachs's Salveen Richter in a report issued on July 20. However, on July 23, BMO Capital assigned a Buy rating to Gilead Sciences (NASDAQ: GILD). Based on Gilead Sciences' latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $6.96 billion and a net profit of $2.02 billion. In comparison, last year the company earned a revenue of $6.67 billion and had a net profit of $1.32 billion Read More on GILD: